Dexamethasone

Dexamethasone

Drug monograph · NCLEX study reference
Trade names	Decadron
Therapeutic class	Anti-inflammatory, immunosuppressant, antiemetic
Pharmacologic class	Long-acting corticosteroid
Onset / peak / duration	Long duration up to 3 days.
Half-life / level	Biologic effect 36 to 72 hours.
Routes	PO (oral), IV, IM
High-alert (ISMP)	No
Black box warning	None
Antidote / reversal	None; taper.
Pregnancy / lactation	Used selectively in obstetrics and oncology.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Dexamethasone (brand name Decadron) — Anti-inflammatory, immunosuppressant, antiemetic; Long-acting corticosteroid.

Identification

• Therapeutic class: Anti-inflammatory, immunosuppressant, antiemetic.
• Pharmacologic class: Long-acting corticosteroid.

Pharmacology

• Mechanism of action: Potent, long-acting corticosteroid with minimal mineralocorticoid effect.
• Onset / peak / duration: Long duration up to 3 days.
• Half-life / therapeutic level: Biologic effect 36 to 72 hours.

Clinical use

• Indications: Cerebral edema, chemotherapy-induced nausea, severe inflammation, croup, certain cancers, fetal lung maturity (alternative to betamethasone).
• Usual dose, route, frequency: PO, IV, or IM dosed by indication.
• Maximum dose / adjustments: Lowest effective dose; taper after prolonged use.

Safety

• Contraindications: Systemic fungal infection.
• Black box warning: None.
• Interactions: Same corticosteroid interactions.
• Pregnancy / lactation: Used selectively in obstetrics and oncology.
• High-alert: No.

Adverse effects

• Common side effects: Hyperglycemia, insomnia, mood changes, increased appetite.
• Serious effects to report: Infection, hyperglycemia, GI bleeding, adrenal suppression.
• Antidote / reversal: None; taper.

Nursing process

• Assessment before administration: Glucose, infection signs.
• Interventions during therapy: Give early in the day to limit insomnia.
• Monitor: Glucose, blood pressure, infection, neuro status if for cerebral edema.
• Evaluation / expected outcome: Reduced edema, controlled nausea, reduced inflammation.

Patient teaching

• Patient teaching: May raise blood sugar and disturb sleep.
• Notify provider if: Signs of infection, severe mood changes.
• Administration tips: Morning dosing when possible; with food.